HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.

AuthorsB Poncet, T Bachelot, C Colin, H Orfeuvre, C Ganne, P Y Péaud, J P Jacquin, B Salles, J D Tigaud, I Méchin-Crétinon, F Maréchal, V Trillet-Lenoir
JournalClinical oncology (Royal College of Radiologists (Great Britain)) (Clin Oncol (R Coll Radiol)) Vol. 19 Issue 2 Pg. 162-3 (Mar 2007) ISSN: 0936-6555 [Print] England
PMID17357239 (Publication Type: Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents (therapeutic use)
  • Breast Neoplasms (drug therapy, economics, secondary)
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Middle Aged
  • Prospective Studies
  • Receptor, ErbB-2 (metabolism)
  • Trastuzumab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: